AbbVie and Immunome have announced a worldwide multi-year collaboration and option agreement to discover multiple oncology targets using Immunome’s discovery engine. Under the terms of the agreement, ...

--AbbVie today announced submission of a Biologics License Application to the U.S. Food and Drug Administration for trenibotulinumtoxinE for the treatment of moderate to severe glabellar lines.

MADISON, Wis. -- A global biopharmaceutical company headquartered in North Chicago has announced the acquisition of Madison-based Nimble Therapeutics for $200 million.

AbbVie (ABBV-0.35%) and Pfizer (PFE-0.88%) especially stand out. In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss which of these ...

Also Read: AbbVie To Present Cancer Trial Data At Upcoming ASCO Event With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a ...

Alabama's animal identification rule went into effect October 1, 2012, and began being enforced January 1, 2013. Why is Alabama requiring animal identification?

AbbVie has announced a new partnership with precision medicine company Frontier Medicines to discover and develop small molecules therapeutics for difficult-to-treat protein targets. The multi-year ...

AbbVie's trailing-12-month (TTM) revenue is $55 billion. By the end of this year, management expects two medicines, Skyrizi and Rinvoq, to bring in a total of $16 billion, making them a ...

AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

@FiercePharma: Here's evidence of Vivus growth expectations: New HQ space almost 3X the size of current offices. More | Follow @FiercePharma @EricPFierce: The FDA approved nearly a dozen new ...